Shows
RealTalk MSEpisode 403: Moving Toward a Biologically Based Description of MS with Dr. Bruce Bebo, Dr. Daniel Ontaneda, and Kathy Smith Last week, the National Multiple Sclerosis Society and the European Committee for Treatment and Research in Multiple Sclerosis convened a meeting in Dublin, Ireland, to dive deeper into what a new framework for describing MS might look like. There's still a tremendous amount of work to be done here. But, considering that whatever language is eventually adopted will affect every person living with MS, I want to keep you fully informed on this important work. So I'm devoting this entire episode of the podcast to sharing conversations I had with three of the attendees at the meeting in Dublin. ...2025-05-2037 min
NeurologyLive® Mind Moments®Neurology Unwrapped: 2024’s Most Intriguing ConversationsWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this special episode, we’ve compiled some of the most compelling conversations from Mind Moments podcast episodes throughout 2024. These discussions spotlight groundbreaking research and advancements in neurology that are propelling the field forward. The NeurologyLive team also explored the impact of several newly FDA-approved therapies, offering clinicians valuable insights into what these treatments mean for patient care and their practical use in the clinic. Featured in this week’s episode, in order of appearance, are:2024-12-2725 minNeurologyLive® Mind Moments®Understanding Major Changes to New McDonald Criteria for Multiple SclerosisWelcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Daniel Ontaneda, MD, PhD, a staff member of the Cleveland Clinic Mellen Center for Multiple Sclerosis, provided an in-depth overview on the newly announced McDonald criteria to diagnose multiple sclerosis (MS). Ontaneda, who also serves as an assistant professor of neurology, discussed the most notable changes to the criteria and how it may help towards improving rates of misdiagnosis and missed diagnosis. He spoke on the incorporation of new biomarkers, such as ce...2024-10-0427 min
The ECTRIMS PodcastArtificial Intelligence in MS Research Artificial intelligence (AI) can be a powerful tool to help enhance our understanding of MS disease processes, improve our diagnostic accuracy, better predict disease course, and identify optimal treatments. How is AI being used in MS research currently and what may it be able to do in the future? Host Alan Thompson, Editor in Chief of MS Journal, talks with Arman Eshaghi of the Queen Square Institute of Neurology, University College London, and Daniel Ontaneda of the Cleveland Clinic Neurological Institute’s Mellen Center for Multiple Sclerosis in the United States.2024-05-1624 minNeurologyLive® Mind Moments®Reviewing ACTRIMS 2024Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Daniel Ontaneda, MD, an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine, sat down to discuss the recently concluded Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. Ontaneda, program committee vice-chair of the meeting, provided insight on a number of notable sessions and discussions that highlighted the recent advances in the MS field. In addition, he talked about the need to innovate clinical trials, ways to...2024-03-2230 min
MS News & PerspectivesJenn sits with neurologist and researcher Dr. Daniel OntanedaDaniel Ontaneda, MD, PhD, FAAN, is a staff neurologist and Director of Research for the Mellen Center for Multiple Sclerosis, part of the Neurological Institute at Cleveland Clinic.
Join them as they discuss the misdiagnosis of MS, gaps in current diagnostic criteria, and how artificial intelligence could be used to aid diagnostic accuracy.
Join the conversation on our MS forums: www.multiplesclerosisnewstoday.com/forums/
Follow us on social media:
Instagram - www.instagram.com/msnewstoday/
Facebook - www.facebook.com/multiplesclerosisnewstoday
Twitter - www.twitter.com/msnewstoday
For more news on Multiple Sclerosis...2024-02-2931 min
RealTalk MSEpisode 329: Revisiting the Pathways To Cures Global SummitThe holiday season provides me with an opportunity to indulge in what's become a RealTalk MS tradition. I reserve the last two episodes of the year to revisit the most compelling,and important conversations that I've had over the past year. This week, I'm revisiting the conversations I had at the Pathways To Cures Global Summit that took place in New York last May. The National MS Society brought together the best and brightest minds in MS research, the CEOs of major MS Societies, representatives from the pharmaceutical industry, and people affected by MS to u...2023-12-1948 min
RealTalk MSECTRIMS EXTRA with Dr. Daniel OntanedaWith more than 9,000 MS researchers and clinicians in attendance, the 2023 combined ECTRIMS-ACTRIMS meeting in Milan was the largest MS research conference in the world. During the meeting, I had an opportunity to talk with some of the best and brightest minds in MS research and clinical practice. This is your invitation to listen in on my ECTRIMS EXTRA conversation with Dr. Daniel Ontaneda. Dr. Ontaneda is a neurologist at the Cleveland Clinic Neurological Institute's Mellen Center for Multiple Sclerosis and, while attending the ECTRIMS-ACTRIMS meeting, Dr. Ontaneda co-chaired a scientific session on artificial i...2023-10-2809 min
RealTalk MSFrom the Pathways To Cures Global Summit (Part 2)Don't miss the second installment of our Pathways To Cures Global Summit coverage. For this unprecedented event, the National MS Society brought together the best and brightest minds in MS research, the CEOs of major MS Societies, representatives from the pharmaceutical industry, and people affected by MS to update the scientific foundation of the Pathways To Cures research roadmap and set the global MS research agenda for the next 3-5 years. In Part 2 of our coverage, we're taking you back inside this historic meeting, where you'll hear from more of the top MS experts in t...2023-05-1637 min
Climate ClinicBe the Expert: Episode 19: Neurological diseases and climate changeIn our latest show, Marc and Adesh discuss the findings from a scoping Review that was published recently in the journal, 'Neurology'. The article was titled "Impacts of Climate Change and Air Pollution on Neurologic Health, Disease, and Practice". The authors were Shreya Louis, Alise K. Carlson, Abhilash Suresh, Joshua Rim, Mary Ann Mays, Daniel Ontaneda and Andrew Dhawan.
Article: https://doi.org/10.1212/WNL.00000000002016302023-04-0527 min
The ECTRIMS PodcastECTRIMS 2022 For People with MS: Part 1Dr. Daniel Ontaneda from the Cleveland Clinic speaks about promising, new mid-term research data for people with MS unveiled during the October 2022 ECTRIMS Congress. 2022-12-1738 min
Iglesia Luz Y Verdad Brigham CityCon Dios No Se Juega - Pastor Mario OntanedaPuedes visitar y suscribirte en nuestro canal de Youtube. https://www.youtube.com/channel/UCNLq4R6FLBI28wrjBorqjkg
¡Dios te bendiga!
Siguenos en nuestra pagina de Facebook y mira nuestros servicios en vivo. https://www.facebook.com/luzyverdadbrigham/
Necesitas mas informacion contacta a nuestro Pastor Daniel Cid en su Whatsapp al +1 801 644 4851. 2022-04-161h 08NeurologyLive® Mind Moments®Highlights From the AAN Annual MeetingWelcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD. Each of them discussed data that they respectively presented at the American Academy of Neurology Annual Meeting. These presentations included novel tools for tracking cognitive decline, analyses of subpopulations of patients with migraine treated with new medicines, the disparities faced by women and Black individuals...2021-04-3036 min
RealTalk MSProgressive MS Research, Treatment, and Rehabilitation with Dr. Kathy Zackowski and Dr. Daniel OntanedaAbout 80% of the people with relapsing-remitting MS will eventually be diagnosed with secondary progressive MS. At that point, their remissions stop and their MS symptoms continue to worsen. And about 15% of the people diagnosed with MS are diagnosed from the beginning with primary progressive MS. So identifying ways to optimally treat progressive MS is a priority. Joining me with updates on progressive MS research, treatment, and rehabilitation are Dr. Kathy Zackowski and Dr. Daniel Ontaneda. Dr. Ontaneda is an associate professor of Neurology at the Cleveland Clinic Lerner College of Medicine of Case We...2021-03-3039 min
Sin audioHow Spoon Made Their Greatest HitsSpoon's Britt Daniel, Jim Eno and Alex Fischel tell the story of the band and the making of songs on their new best-of compilation2019-08-2740 min
eMultipleSclerosis ReviewIndividualizing MS Treatment: Practical ApplicationsIn this podcast, Drs. Daniel Ontaneda, Jenny Feng and Gabrielle Macaron from the Cleveland Clinic follow up on their recent eMS Newsletter Issue (V2; No.5) to discuss some of the practical applications of individualizing MS therapy. Take our post-test to claim CME credits. To read a companion newsletter click here. Hosted on Acast. See acast.com/privacy for more information.2019-06-2925 min
Listen to The Lancet NeurologyCerebral white matter demyelination in multiple sclerosisBruce Trapp and Daniel Ontaneda discuss their retrospective study investigating cortical neuronal loss and cerebral white-matter demyelination in mulitple sclerosis.2018-09-1815 min
The Lancet Neurology in conversation withCerebral white matter demyelination in multiple sclerosisBruce Trapp and Daniel Ontaneda discuss their retrospective study investigating cortical neuronal loss and cerebral white-matter demyelination in mulitple sclerosis.Continue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv2018-09-1816 min